Comparison Fenofibrate, Rosiglitazone, or Weight Loss to Decrease Cardiovascular Risk in Insulin Resistant Dyslipidemic Individuals.
Phase of Trial: Phase II
Latest Information Update: 16 Jan 2017
At a glance
- Drugs Fenofibrate (Primary) ; Rosiglitazone (Primary)
- Indications Hypertriglyceridaemia; Insulin resistance
- Focus Therapeutic Use
- 09 May 2016 New trial record